

## **PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN**

### **Summary of Risk Management Plan for Enalapril / Lercanidipine Viatriis (Enalapril/lercanidipine)**

This is a summary of the risk management plan (RMP) for Enalapril / Lercanidipine Viatriis. The RMP details important risks of enalapril/lercanidipine, how these risks can be minimised, and how more information will be obtained about enalapril/lercanidipine's risks and uncertainties (missing information).

Enalapril / Lercanidipine Viatriis's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how it should be used.

#### **I. The Medicine and What it is Used For**

Enalapril / Lercanidipine Viatriis is authorised for treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled with enalapril 20 mg lercanidipine 20 mg and given concurrently as separate tablets. It contains enalapril/lercanidipine as the active substance and it is given by oral route of administration.

#### **II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks**

Important risks of Enalapril / Lercanidipine Viatriis, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

#### **II.A List of Important Risks and Missing Information**

Important risks of Enalapril / Lercanidipine Viatriis are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Enalapril / Lercanidipine Viatriis. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal

## Risk Management Plan Enalapril / Lercanidipine Version 0.3

product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.);

**Table 3: Part VI.1- Summary of safety concerns**

<b>List of Important Risks and Missing Information</b>	
Important Identified Risks	None
Important Potential Risks	None
Missing Information	None

### II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### II.C Post-Authorisation Development Plan

#### II.C.1 Studies Which are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Enalapril / Lercanidipine Viatris.

#### II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Enalapril / Lercanidipine Viatris.